Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Brucellosis Market Trends

ID: MRFR/LS/3722-HCR
90 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Brucellosis Market research report– by species (Brucella suis, B. abortus, B. melitensis), Diagnosis (serological tests, molecular techniques, bone marrow biopsy, CT, MRI), Treatment (vaccine, antibiotics), End user– Forecast till 2035.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Brucellosis Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Brucellosis Market

Market trends are affected by Brucellosis, a bacterial disease that affects humans and animals, globally. Areas rich in cattle have significant market share. Asia, the Middle East, and Latin America are included. The industry is booming due to increased awareness and better diagnostics. Governments and healthcare organizations are educating the public and healthcare professionals about brucellosis to enhance early detection and treatment. This aims to educate the public about the condition. Increased research and development is another notable brucellosis market trend. Pharmaceutical companies and academic institutions are developing new drugs and vaccines to fight Brucellosis more effectively. This is done to meet demand for enhanced treatment options. Technological advances in diagnostic and treatment technologies are influencing industrial trends. Rapid, accurate diagnostic tests and innovative treatment methods are improving patient outcomes and growing the market. Government actions to regulate and prevent brucellosis are affecting market dynamics. Governments and pharmaceutical companies are creating a market-friendly climate via financial aid, regulatory frameworks, and collaboration. Veterinary healthcare is getting more attention since human and animal health are interdependent. Brucellosis is zoonotic, hence the market is adopting a combined veterinary and human healthcare strategy. The worldwide commerce in cattle and animal products spreads Brucellosis. In places where the illness is common and stakeholders are striving to restrict its transmission, international commerce rules and surveillance are influencing market patterns. This is particularly true in regulated areas. Pharmaceutical corporations, research institutes, and healthcare groups are forming synergistic alliances to conquer Brucellosis. These collaborations promote resource, information, and technology exchange, which helps create full solutions. Developing nations with high Brucellosis rates are becoming market growth priorities. Market growth in these areas is driven by increased access to medical services, better healthcare infrastructure, and healthcare awareness. Patient-centered techniques are becoming more essential in the Brucellosis sector. Personalized treatment regimens, patient education programs, and support networks are becoming more common to address Brucellosis' consequences on communities and individuals.

Author
Author Profile
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the Brucellosis Market as of 2024?

<p>The Brucellosis Market was valued at 657.55 USD Million in 2024.</p>

What is the projected market valuation for the Brucellosis Market in 2035?

<p>The projected valuation for the Brucellosis Market in 2035 is 1380.04 USD Million.</p>

What is the expected CAGR for the Brucellosis Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Brucellosis Market during the forecast period 2025 - 2035 is 6.93%.</p>

Which companies are considered key players in the Brucellosis Market?

<p>Key players in the Brucellosis Market include Zoetis, Merck Animal Health, Boehringer Ingelheim, and others.</p>

What are the main application segments of the Brucellosis Market?

<p>The main application segments include Diagnosis, Vaccination, Research, and Surveillance.</p>

How much was the Vaccination segment valued at in 2024?

The Vaccination segment was valued at 200.0 USD Million in 2024.

What is the projected value of the Veterinary end-use segment by 2035?

The Veterinary end-use segment is projected to reach 400.0 USD Million by 2035.

Which pathogen type segment had the highest valuation in 2024?

The Brucella melitensis pathogen type segment had the highest valuation at 200.0 USD Million in 2024.

What are the different test types used in the Brucellosis Market?

Test types include Serological Tests, Molecular Tests, Culture Tests, and Skin Tests.

What was the valuation of the Skin Tests segment in 2024?

The Skin Tests segment was valued at 207.55 USD Million in 2024.

Market Summary

As per MRFR analysis, the Brucellosis Market Size was estimated at 657.55 USD Million in 2024. The Brucellosis industry is projected to grow from 710.65 USD Million in 2025 to 1380.04 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 6.93% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Brucellosis Market is experiencing notable growth driven by increased awareness and technological advancements.

  • Rising awareness of zoonotic diseases is propelling the demand for brucellosis diagnostics and vaccinations. Advancements in diagnostic technologies are enhancing the accuracy and speed of brucellosis detection, particularly in healthcare facilities. Research and development initiatives are fostering innovation in vaccination programs, especially within veterinary clinics. The increasing incidence of brucellosis and government initiatives are driving market growth, particularly in North America and the Asia-Pacific region.

Market Size & Forecast

2024 Market Size 657.55 (USD Million)
2035 Market Size 1380.04 (USD Million)
CAGR (2025 - 2035) 6.93%
Largest Regional Market Share in 2024 North America

Major Players

Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Ceva Santé Animale (FR), Vetoquinol (FR), Heska Corporation (US), Elanco Animal Health (US), Virbac (FR)

Market Trends

The Brucellosis Market is currently experiencing notable developments driven by a combination of factors including rising awareness of zoonotic diseases and advancements in diagnostic technologies. The increasing incidence of brucellosis, particularly in regions with high livestock populations, has prompted governments and health organizations to prioritize control measures. This heightened focus on prevention and treatment is likely to stimulate growth in the market, as stakeholders seek effective solutions to combat this infectious disease. Furthermore, the integration of innovative technologies in diagnostics and therapeutics appears to enhance the overall management of brucellosis, potentially leading to improved patient outcomes and reduced transmission rates. In addition, the Brucellosis Market is influenced by ongoing research initiatives aimed at developing vaccines and novel treatment options. Collaborations between public health entities and private sector organizations may foster a more robust response to the challenges posed by brucellosis. As awareness continues to expand, it seems plausible that investment in research and development will increase, thereby contributing to the market's evolution. Overall, the Brucellosis Market is poised for growth, driven by a multifaceted approach to disease management and prevention, which may ultimately lead to a decline in the prevalence of this condition across affected regions.

Rising Awareness of Zoonotic Diseases

The growing recognition of zoonotic diseases, including brucellosis, is prompting increased public health initiatives. This trend indicates a shift towards proactive measures aimed at preventing transmission from animals to humans, thereby enhancing overall community health.

Advancements in Diagnostic Technologies

Innovations in diagnostic methods are transforming the Brucellosis Market. Enhanced testing capabilities allow for quicker and more accurate identification of infections, which is crucial for effective management and control of the disease.

Research and Development Initiatives

Ongoing research efforts focused on vaccine development and novel treatment strategies are shaping the future of the Brucellosis Market. Collaborative projects between various stakeholders may lead to breakthroughs that significantly impact disease prevention and management.

Brucellosis Market Market Drivers

Rising Incidence of Brucellosis

The increasing incidence of brucellosis globally is a primary driver for the Global Brucellosis Market Industry. In 2024, the estimated market size is 0.09 USD Billion, reflecting heightened awareness and reporting of the disease. Brucellosis Market, primarily affecting livestock, poses significant health risks to humans, particularly in regions with high animal husbandry practices. Countries with endemic brucellosis face economic burdens due to livestock losses and healthcare costs. This situation necessitates improved diagnostic and therapeutic solutions, thereby propelling market growth. As awareness spreads, the demand for effective vaccines and treatments is likely to increase, further stimulating the Global Brucellosis Market Industry.

Government Initiatives and Funding

Government initiatives aimed at controlling and eradicating brucellosis are pivotal for the Global Brucellosis Market Industry. Various countries are implementing vaccination programs and surveillance systems to monitor and reduce the disease's prevalence. Increased funding for research and development of vaccines and treatments is expected to enhance market growth. For instance, public health campaigns focusing on education and prevention strategies are likely to raise awareness among farmers and the general population. This proactive approach not only aims to reduce infection rates but also encourages investment in the development of innovative solutions, thereby fostering a more robust Global Brucellosis Market Industry.

Growing Awareness of Zoonotic Diseases

The rising awareness of zoonotic diseases, including brucellosis, is driving the Global Brucellosis Market Industry. Public health organizations are emphasizing the importance of understanding how diseases can transfer from animals to humans. This awareness is particularly relevant in regions where livestock farming is prevalent. As consumers become more informed about the risks associated with zoonotic infections, there is a growing demand for preventive measures, including vaccination and improved food safety practices. This trend is likely to lead to increased investments in research and development, ultimately contributing to the expansion of the Global Brucellosis Market Industry as stakeholders seek to mitigate risks associated with brucellosis.

Advancements in Diagnostic Technologies

Technological advancements in diagnostic methods are significantly influencing the Global Brucellosis Market Industry. Enhanced diagnostic tools, such as serological tests and molecular techniques, allow for quicker and more accurate detection of brucellosis. This is crucial for managing outbreaks and implementing control measures effectively. As these technologies become more accessible, healthcare providers are likely to adopt them, leading to an increase in reported cases and subsequent demand for treatment options. The integration of these advanced diagnostics into routine veterinary practices may also contribute to the market's growth, as early detection can mitigate the economic impact of the disease on livestock and public health.

Projected Market Growth and Economic Potential

The Global Brucellosis Market Industry is projected to experience substantial growth, with estimates indicating a market size of 0.81 USD Billion by 2035. This growth trajectory, characterized by a compound annual growth rate (CAGR) of 22.62% from 2025 to 2035, suggests a robust demand for brucellosis-related products and services. Factors contributing to this growth include increased investments in vaccine development, enhanced diagnostic capabilities, and rising awareness of the disease's impact on public health. As the market evolves, stakeholders are likely to explore innovative solutions to address the challenges posed by brucellosis, thereby solidifying the industry's position in the global healthcare landscape.

Market Segment Insights

By Application: Diagnosis (Largest) vs. Vaccination (Fastest-Growing)

The application segment of the Brucellosis Market is primarily divided into Diagnosis, Vaccination, Research, and Surveillance. Currently, the Diagnosis segment holds the largest share due to the increasing prevalence of brucellosis and the growing focus on effective detection methods. Vaccination, while smaller in comparison, is rapidly gaining traction as the importance of preventive measures becomes more recognized in combating the disease.

Diagnosis (Dominant) vs. Vaccination (Emerging)

The Diagnosis segment is characterized by innovative techniques and tests for brucellosis detection, including serological tests and molecular methods that have improved accuracy and speed. On the other hand, Vaccination represents an emerging area with a growing pipeline of vaccines aimed at preventing the disease. The increasing investment in research and development, alongside the heightened awareness of zoonotic diseases, is driving growth in the Vaccination segment, making it a pivotal focus for stakeholders in the market.

By End Use: Veterinary (Largest) vs. Pharmaceuticals (Fastest-Growing)

<p>The Brucellosis market is segmented into four primary end-use categories: Healthcare, Veterinary, Pharmaceuticals, and Research Institutions. Among these, the Veterinary segment holds the largest market share, driven by increased awareness and preventive measures against this zoonotic infection in livestock. The substantial investments in veterinary infrastructure globally further solidify its dominant position, reflecting its critical role in public health through livestock management. Meanwhile, the Pharmaceuticals segment, while currently smaller, is witnessing rapid growth, spurred by advancements in drug development and increasing demand for effective treatments against the disease.</p>

<p>Veterinary (Dominant) vs. Pharmaceuticals (Emerging)</p>

<p>The Veterinary end-use segment is recognized as the dominant player in the Brucellosis market, primarily due to the urgent need for effective control and prevention strategies in livestock. Its solid growth is anchored in livestock health initiatives and government regulations aimed at reducing the incidence of Brucellosis. Conversely, the Pharmaceuticals segment is emerging as a crucial area, driven by innovations in vaccine development and antibiotics that combat Brucellosis in humans and animals. This segment is gaining traction due to the increasing focus on developing targeted therapies and research-driven solutions, highlighting a shift towards personalized medicine and better management of the disease.</p>

By Pathogen Type: Brucella melitensis (Largest) vs. Brucella abortus (Fastest-Growing)

<p>In the Brucellosis Market, Brucella melitensis holds the largest share due to its higher prevalence in human infections compared to other strains. This pathogen is commonly associated with unpasteurized dairy products, leading to elevated levels of awareness and resulting in preventative measures and treatment regimens. On the other hand, Brucella abortus, primarily affecting cattle, is showing significant growth trends, particularly in regions focusing on livestock disease management, thereby catering to agricultural and veterinary sectors effectively.</p>

<p>Brucella melitensis (Dominant) vs. Brucella suis (Emerging)</p>

<p>Brucella melitensis stands out as the dominant pathogen impacting the Brucellosis Market, primarily due to its association with zoonotic infections in humans. Its prevalence has driven substantial awareness and response measures globally. In contrast, Brucella suis, while being an emerging pathogen, is gaining attention due to its potential to affect wild and domestic pigs, leading to economic losses in the swine industry. As studies continue to unveil its impacts on both veterinary and public health, interest in targeted interventions and research on Brucella suis is on the rise, creating new opportunities within the market.</p>

By Test Type: Serological Tests (Largest) vs. Molecular Tests (Fastest-Growing)

The Brucellosis Market is distinctly characterized by its test types, with serological tests holding the largest market share due to their widespread adoption in diagnosing brucellosis. These tests are favored for their reliability and efficiency in identifying anti-brucella antibodies in patients. In contrast, molecular tests are increasingly gaining traction and represent the fastest-growing segment due to advancements in technology that allow for rapid and accurate detection of Brucella DNA, showcasing a shift in preference towards more precise diagnostic methods. Analyzing growth trends within the 'Test Type' segment reveals significant drivers contributing to the rising adoption of molecular tests. Factors such as the increasing prevalence of brucellosis globally, coupled with rising healthcare investments in diagnostic technologies, are propelling the growth of this segment. The ongoing efforts to improve diagnostic accuracy and reduce testing times are also spurring demand, making molecular tests a key focus for innovation in the market.

Serological Tests (Dominant) vs. Culture Tests (Emerging)

Serological tests remain the dominant choice in the Brucellosis Market due to their extensive use in routine diagnostics across various healthcare settings. These tests are not only cost-effective but also provide rapid results, making them suitable for large-scale screenings. On the other hand, culture tests, while currently positioned as an emerging segment, are vital for confirming brucellosis diagnosis through the isolation of the bacteria from infected tissues or fluids. Although culture tests have a longer turnaround time, their specificity complements serological testing, thus enhancing diagnostic accuracy. As treatment protocols evolve, the integration of these two testing methods is likely to optimize patient outcomes and support public health initiatives aimed at controlling brucellosis.

Get more detailed insights about Brucellosis Market Research Report - Forecast to 2035

Regional Insights

North America : Market Leader in Brucellosis

North America holds a significant position in the Brucellosis market, with a market size of $328.78M in 2025. The region's growth is driven by increasing livestock populations, heightened awareness of animal health, and stringent regulations aimed at controlling zoonotic diseases. The demand for effective vaccines and diagnostics is on the rise, supported by government initiatives to enhance animal health standards and reduce disease prevalence. The competitive landscape in North America is robust, featuring key players such as Zoetis, Merck Animal Health, and Elanco Animal Health. These companies are investing in R&D to innovate and improve treatment options. The U.S. leads the market, followed by Canada, with a strong focus on veterinary healthcare. The presence of established firms and a growing emphasis on animal welfare further solidify North America's market dominance.

Europe : Emerging Market Dynamics

Europe's Brucellosis market is valued at $215.03M in 2025, driven by increasing livestock trade and regulatory frameworks promoting animal health. The European Union has implemented stringent regulations to control Brucellosis, enhancing the demand for effective vaccines and diagnostic tools. The focus on sustainable farming practices and animal welfare is also propelling market growth, as consumers demand higher standards in food safety and quality. Leading countries in this region include Germany, France, and the UK, where companies like Boehringer Ingelheim and Ceva Santé Animale are prominent. The competitive landscape is characterized by innovation and collaboration among key players to develop advanced veterinary solutions. The European market is witnessing a shift towards preventive healthcare, with an emphasis on vaccination programs and disease management strategies.

Asia-Pacific : Growing Awareness and Demand

The Asia-Pacific region, with a market size of $85.15M in 2025, is witnessing a surge in demand for Brucellosis management solutions. Factors such as increasing livestock farming, rising awareness of animal health, and government initiatives to combat zoonotic diseases are driving market growth. Countries like India and China are focusing on improving veterinary healthcare standards, which is expected to boost the demand for vaccines and diagnostics in the coming years. The competitive landscape is evolving, with both local and international players entering the market. Companies like Virbac and Heska Corporation are expanding their presence in this region. The growing emphasis on food safety and quality assurance is prompting investments in veterinary health, making Asia-Pacific a promising market for Brucellosis solutions.

Middle East and Africa : Untapped Market Potential

The Middle East and Africa region, with a market size of $28.59M in 2025, presents significant growth potential in the Brucellosis market. The increasing prevalence of livestock diseases and the need for effective management solutions are driving demand. Government initiatives aimed at improving animal health and food safety standards are also contributing to market growth. The region is gradually recognizing the importance of veterinary healthcare, leading to increased investments in disease control measures. Countries like South Africa and Kenya are at the forefront of this market, with local players and international companies exploring opportunities. The competitive landscape is characterized by a mix of established firms and emerging players, focusing on innovative solutions to address Brucellosis. The region's untapped potential makes it an attractive area for investment and development in veterinary health solutions.

Key Players and Competitive Insights

The Brucellosis Market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansions. Key players such as Zoetis (US), Merck Animal Health (US), and Boehringer Ingelheim (DE) are actively pursuing strategies that enhance their market positioning. For instance, Zoetis (US) has focused on developing advanced diagnostic tools and vaccines, which are critical in managing brucellosis outbreaks. Meanwhile, Merck Animal Health (US) emphasizes a robust portfolio of vaccines and therapeutics, aiming to leverage its research capabilities to address emerging challenges in animal health. Boehringer Ingelheim (DE) appears to be concentrating on strategic acquisitions to bolster its product offerings, thereby enhancing its competitive edge in the market.The business tactics employed by these companies reflect a trend towards localizing manufacturing and optimizing supply chains to meet regional demands effectively. The market structure is moderately fragmented, with several players vying for market share, yet the collective influence of these key companies is substantial. Their strategies not only enhance their individual market positions but also contribute to a more dynamic competitive environment, where innovation and responsiveness to market needs are paramount.
In November Zoetis (US) announced the launch of a new vaccine specifically targeting brucellosis in cattle, which is expected to significantly reduce infection rates in livestock. This strategic move underscores the company's commitment to innovation and its proactive approach to addressing the challenges posed by brucellosis. The introduction of this vaccine could potentially reshape vaccination protocols and improve herd health, thereby enhancing productivity in the agricultural sector.
In October Merck Animal Health (US) expanded its distribution network in Latin America, aiming to increase access to its brucellosis vaccine. This expansion is strategically important as it allows Merck to tap into emerging markets where brucellosis remains a significant concern. By enhancing its presence in these regions, the company is likely to strengthen its market share and foster long-term relationships with local veterinarians and farmers.
In September Boehringer Ingelheim (DE) completed the acquisition of a biotechnology firm specializing in animal health diagnostics. This acquisition is indicative of the company's strategy to integrate advanced diagnostic capabilities into its existing product line, thereby providing comprehensive solutions for brucellosis management. The integration of these technologies may enhance the company's competitive positioning by offering veterinarians and farmers more effective tools for disease prevention and management.
As of December the competitive trends in the Brucellosis Market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) in diagnostics and treatment protocols. Strategic alliances among key players are shaping the landscape, fostering innovation and collaboration. The shift from price-based competition to a focus on technological advancements and supply chain reliability is evident. Companies that prioritize innovation and adaptability are likely to emerge as leaders in this evolving market.

Key Companies in the Brucellosis Market include

Industry Developments

Future Outlook

Brucellosis Market Future Outlook

The Brucellosis Market is projected to grow at a 6.93% CAGR from 2025 to 2035, driven by increased awareness, advancements in diagnostics, and rising livestock health concerns.

New opportunities lie in:

  • <p>Development of rapid diagnostic kits for field use Expansion of <a href="https://www.marketresearchfuture.com/reports/telemedicine-services-market-68013">telemedicine services</a> for remote consultations Investment in vaccine research for livestock and wildlife</p>

By 2035, the Brucellosis Market is expected to achieve substantial growth and enhanced global health initiatives.

Market Segmentation

Brucellosis Market End Use Outlook

  • Healthcare Facilities
  • Research Laboratories
  • Veterinary Clinics
  • Pharmaceutical Companies

Brucellosis Market Test Type Outlook

  • Serological Tests
  • Molecular Tests
  • Culture Tests
  • Skin Tests

Brucellosis Market Application Outlook

  • Diagnosis
  • Vaccination
  • Research
  • Surveillance

Brucellosis Market Pathogen Type Outlook

  • Brucella abortus
  • Brucella melitensis
  • Brucella suis
  • Brucella canis

Report Scope

MARKET SIZE 2024 657.55(USD Million)
MARKET SIZE 2025 710.65(USD Million)
MARKET SIZE 2035 1380.04(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.93% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Ceva Santé Animale (FR), Vetoquinol (FR), Heska Corporation (US), Elanco Animal Health (US), Virbac (FR)
Segments Covered Application, End Use, Pathogen Type, Test Type
Key Market Opportunities Advancements in diagnostic technologies enhance early detection and treatment options in the Brucellosis Market.
Key Market Dynamics Rising regulatory scrutiny and advancements in diagnostics are reshaping the competitive landscape of the Brucellosis Market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Brucellosis Market as of 2024?

<p>The Brucellosis Market was valued at 657.55 USD Million in 2024.</p>

What is the projected market valuation for the Brucellosis Market in 2035?

<p>The projected valuation for the Brucellosis Market in 2035 is 1380.04 USD Million.</p>

What is the expected CAGR for the Brucellosis Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Brucellosis Market during the forecast period 2025 - 2035 is 6.93%.</p>

Which companies are considered key players in the Brucellosis Market?

<p>Key players in the Brucellosis Market include Zoetis, Merck Animal Health, Boehringer Ingelheim, and others.</p>

What are the main application segments of the Brucellosis Market?

<p>The main application segments include Diagnosis, Vaccination, Research, and Surveillance.</p>

How much was the Vaccination segment valued at in 2024?

The Vaccination segment was valued at 200.0 USD Million in 2024.

What is the projected value of the Veterinary end-use segment by 2035?

The Veterinary end-use segment is projected to reach 400.0 USD Million by 2035.

Which pathogen type segment had the highest valuation in 2024?

The Brucella melitensis pathogen type segment had the highest valuation at 200.0 USD Million in 2024.

What are the different test types used in the Brucellosis Market?

Test types include Serological Tests, Molecular Tests, Culture Tests, and Skin Tests.

What was the valuation of the Skin Tests segment in 2024?

The Skin Tests segment was valued at 207.55 USD Million in 2024.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Application (USD Million)
    2. | | 4.1.1 Diagnosis
    3. | | 4.1.2 Vaccination
    4. | | 4.1.3 Research
    5. | | 4.1.4 Surveillance
    6. | 4.2 Healthcare, BY End Use (USD Million)
    7. | | 4.2.1 Healthcare
    8. | | 4.2.2 Veterinary
    9. | | 4.2.3 Pharmaceuticals
    10. | | 4.2.4 Research Institutions
    11. | 4.3 Healthcare, BY Pathogen Type (USD Million)
    12. | | 4.3.1 Brucella abortus
    13. | | 4.3.2 Brucella melitensis
    14. | | 4.3.3 Brucella suis
    15. | | 4.3.4 Brucella canis
    16. | 4.4 Healthcare, BY Test Type (USD Million)
    17. | | 4.4.1 Serological Tests
    18. | | 4.4.2 Molecular Tests
    19. | | 4.4.3 Culture Tests
    20. | | 4.4.4 Skin Tests
    21. | 4.5 Healthcare, BY Region (USD Million)
    22. | | 4.5.1 North America
    23. | | | 4.5.1.1 US
    24. | | | 4.5.1.2 Canada
    25. | | 4.5.2 Europe
    26. | | | 4.5.2.1 Germany
    27. | | | 4.5.2.2 UK
    28. | | | 4.5.2.3 France
    29. | | | 4.5.2.4 Russia
    30. | | | 4.5.2.5 Italy
    31. | | | 4.5.2.6 Spain
    32. | | | 4.5.2.7 Rest of Europe
    33. | | 4.5.3 APAC
    34. | | | 4.5.3.1 China
    35. | | | 4.5.3.2 India
    36. | | | 4.5.3.3 Japan
    37. | | | 4.5.3.4 South Korea
    38. | | | 4.5.3.5 Malaysia
    39. | | | 4.5.3.6 Thailand
    40. | | | 4.5.3.7 Indonesia
    41. | | | 4.5.3.8 Rest of APAC
    42. | | 4.5.4 South America
    43. | | | 4.5.4.1 Brazil
    44. | | | 4.5.4.2 Mexico
    45. | | | 4.5.4.3 Argentina
    46. | | | 4.5.4.4 Rest of South America
    47. | | 4.5.5 MEA
    48. | | | 4.5.5.1 GCC Countries
    49. | | | 4.5.5.2 South Africa
    50. | | | 4.5.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Zoetis (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Merck Animal Health (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Boehringer Ingelheim (DE)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Ceva Santé Animale (FR)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Vetoquinol (FR)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Heska Corporation (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Elanco Animal Health (US)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Virbac (FR)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | 5.3 Appendix
    65. | | 5.3.1 References
    66. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY APPLICATION
    4. | 6.4 US MARKET ANALYSIS BY END USE
    5. | 6.5 US MARKET ANALYSIS BY PATHOGEN TYPE
    6. | 6.6 US MARKET ANALYSIS BY TEST TYPE
    7. | 6.7 CANADA MARKET ANALYSIS BY APPLICATION
    8. | 6.8 CANADA MARKET ANALYSIS BY END USE
    9. | 6.9 CANADA MARKET ANALYSIS BY PATHOGEN TYPE
    10. | 6.10 CANADA MARKET ANALYSIS BY TEST TYPE
    11. | 6.11 EUROPE MARKET ANALYSIS
    12. | 6.12 GERMANY MARKET ANALYSIS BY APPLICATION
    13. | 6.13 GERMANY MARKET ANALYSIS BY END USE
    14. | 6.14 GERMANY MARKET ANALYSIS BY PATHOGEN TYPE
    15. | 6.15 GERMANY MARKET ANALYSIS BY TEST TYPE
    16. | 6.16 UK MARKET ANALYSIS BY APPLICATION
    17. | 6.17 UK MARKET ANALYSIS BY END USE
    18. | 6.18 UK MARKET ANALYSIS BY PATHOGEN TYPE
    19. | 6.19 UK MARKET ANALYSIS BY TEST TYPE
    20. | 6.20 FRANCE MARKET ANALYSIS BY APPLICATION
    21. | 6.21 FRANCE MARKET ANALYSIS BY END USE
    22. | 6.22 FRANCE MARKET ANALYSIS BY PATHOGEN TYPE
    23. | 6.23 FRANCE MARKET ANALYSIS BY TEST TYPE
    24. | 6.24 RUSSIA MARKET ANALYSIS BY APPLICATION
    25. | 6.25 RUSSIA MARKET ANALYSIS BY END USE
    26. | 6.26 RUSSIA MARKET ANALYSIS BY PATHOGEN TYPE
    27. | 6.27 RUSSIA MARKET ANALYSIS BY TEST TYPE
    28. | 6.28 ITALY MARKET ANALYSIS BY APPLICATION
    29. | 6.29 ITALY MARKET ANALYSIS BY END USE
    30. | 6.30 ITALY MARKET ANALYSIS BY PATHOGEN TYPE
    31. | 6.31 ITALY MARKET ANALYSIS BY TEST TYPE
    32. | 6.32 SPAIN MARKET ANALYSIS BY APPLICATION
    33. | 6.33 SPAIN MARKET ANALYSIS BY END USE
    34. | 6.34 SPAIN MARKET ANALYSIS BY PATHOGEN TYPE
    35. | 6.35 SPAIN MARKET ANALYSIS BY TEST TYPE
    36. | 6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    37. | 6.37 REST OF EUROPE MARKET ANALYSIS BY END USE
    38. | 6.38 REST OF EUROPE MARKET ANALYSIS BY PATHOGEN TYPE
    39. | 6.39 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE
    40. | 6.40 APAC MARKET ANALYSIS
    41. | 6.41 CHINA MARKET ANALYSIS BY APPLICATION
    42. | 6.42 CHINA MARKET ANALYSIS BY END USE
    43. | 6.43 CHINA MARKET ANALYSIS BY PATHOGEN TYPE
    44. | 6.44 CHINA MARKET ANALYSIS BY TEST TYPE
    45. | 6.45 INDIA MARKET ANALYSIS BY APPLICATION
    46. | 6.46 INDIA MARKET ANALYSIS BY END USE
    47. | 6.47 INDIA MARKET ANALYSIS BY PATHOGEN TYPE
    48. | 6.48 INDIA MARKET ANALYSIS BY TEST TYPE
    49. | 6.49 JAPAN MARKET ANALYSIS BY APPLICATION
    50. | 6.50 JAPAN MARKET ANALYSIS BY END USE
    51. | 6.51 JAPAN MARKET ANALYSIS BY PATHOGEN TYPE
    52. | 6.52 JAPAN MARKET ANALYSIS BY TEST TYPE
    53. | 6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    54. | 6.54 SOUTH KOREA MARKET ANALYSIS BY END USE
    55. | 6.55 SOUTH KOREA MARKET ANALYSIS BY PATHOGEN TYPE
    56. | 6.56 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE
    57. | 6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION
    58. | 6.58 MALAYSIA MARKET ANALYSIS BY END USE
    59. | 6.59 MALAYSIA MARKET ANALYSIS BY PATHOGEN TYPE
    60. | 6.60 MALAYSIA MARKET ANALYSIS BY TEST TYPE
    61. | 6.61 THAILAND MARKET ANALYSIS BY APPLICATION
    62. | 6.62 THAILAND MARKET ANALYSIS BY END USE
    63. | 6.63 THAILAND MARKET ANALYSIS BY PATHOGEN TYPE
    64. | 6.64 THAILAND MARKET ANALYSIS BY TEST TYPE
    65. | 6.65 INDONESIA MARKET ANALYSIS BY APPLICATION
    66. | 6.66 INDONESIA MARKET ANALYSIS BY END USE
    67. | 6.67 INDONESIA MARKET ANALYSIS BY PATHOGEN TYPE
    68. | 6.68 INDONESIA MARKET ANALYSIS BY TEST TYPE
    69. | 6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION
    70. | 6.70 REST OF APAC MARKET ANALYSIS BY END USE
    71. | 6.71 REST OF APAC MARKET ANALYSIS BY PATHOGEN TYPE
    72. | 6.72 REST OF APAC MARKET ANALYSIS BY TEST TYPE
    73. | 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. | 6.74 BRAZIL MARKET ANALYSIS BY APPLICATION
    75. | 6.75 BRAZIL MARKET ANALYSIS BY END USE
    76. | 6.76 BRAZIL MARKET ANALYSIS BY PATHOGEN TYPE
    77. | 6.77 BRAZIL MARKET ANALYSIS BY TEST TYPE
    78. | 6.78 MEXICO MARKET ANALYSIS BY APPLICATION
    79. | 6.79 MEXICO MARKET ANALYSIS BY END USE
    80. | 6.80 MEXICO MARKET ANALYSIS BY PATHOGEN TYPE
    81. | 6.81 MEXICO MARKET ANALYSIS BY TEST TYPE
    82. | 6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION
    83. | 6.83 ARGENTINA MARKET ANALYSIS BY END USE
    84. | 6.84 ARGENTINA MARKET ANALYSIS BY PATHOGEN TYPE
    85. | 6.85 ARGENTINA MARKET ANALYSIS BY TEST TYPE
    86. | 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    87. | 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
    88. | 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATHOGEN TYPE
    89. | 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE
    90. | 6.90 MEA MARKET ANALYSIS
    91. | 6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    92. | 6.92 GCC COUNTRIES MARKET ANALYSIS BY END USE
    93. | 6.93 GCC COUNTRIES MARKET ANALYSIS BY PATHOGEN TYPE
    94. | 6.94 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE
    95. | 6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    96. | 6.96 SOUTH AFRICA MARKET ANALYSIS BY END USE
    97. | 6.97 SOUTH AFRICA MARKET ANALYSIS BY PATHOGEN TYPE
    98. | 6.98 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE
    99. | 6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION
    100. | 6.100 REST OF MEA MARKET ANALYSIS BY END USE
    101. | 6.101 REST OF MEA MARKET ANALYSIS BY PATHOGEN TYPE
    102. | 6.102 REST OF MEA MARKET ANALYSIS BY TEST TYPE
    103. | 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. | 6.104 RESEARCH PROCESS OF MRFR
    105. | 6.105 DRO ANALYSIS OF HEALTHCARE
    106. | 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. | 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. | 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. | 6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    110. | 6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    111. | 6.111 HEALTHCARE, BY END USE, 2024 (% SHARE)
    112. | 6.112 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
    113. | 6.113 HEALTHCARE, BY PATHOGEN TYPE, 2024 (% SHARE)
    114. | 6.114 HEALTHCARE, BY PATHOGEN TYPE, 2024 TO 2035 (USD Million)
    115. | 6.115 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE)
    116. | 6.116 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Million)
    117. | 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
    5. | | 7.2.2 BY END USE, 2025-2035 (USD Million)
    6. | | 7.2.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    7. | | 7.2.4 BY TEST TYPE, 2025-2035 (USD Million)
    8. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    9. | | 7.3.1 BY APPLICATION, 2025-2035 (USD Million)
    10. | | 7.3.2 BY END USE, 2025-2035 (USD Million)
    11. | | 7.3.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    12. | | 7.3.4 BY TEST TYPE, 2025-2035 (USD Million)
    13. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    14. | | 7.4.1 BY APPLICATION, 2025-2035 (USD Million)
    15. | | 7.4.2 BY END USE, 2025-2035 (USD Million)
    16. | | 7.4.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    17. | | 7.4.4 BY TEST TYPE, 2025-2035 (USD Million)
    18. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    19. | | 7.5.1 BY APPLICATION, 2025-2035 (USD Million)
    20. | | 7.5.2 BY END USE, 2025-2035 (USD Million)
    21. | | 7.5.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    22. | | 7.5.4 BY TEST TYPE, 2025-2035 (USD Million)
    23. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.6.1 BY APPLICATION, 2025-2035 (USD Million)
    25. | | 7.6.2 BY END USE, 2025-2035 (USD Million)
    26. | | 7.6.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    27. | | 7.6.4 BY TEST TYPE, 2025-2035 (USD Million)
    28. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    29. | | 7.7.1 BY APPLICATION, 2025-2035 (USD Million)
    30. | | 7.7.2 BY END USE, 2025-2035 (USD Million)
    31. | | 7.7.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    32. | | 7.7.4 BY TEST TYPE, 2025-2035 (USD Million)
    33. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.8.1 BY APPLICATION, 2025-2035 (USD Million)
    35. | | 7.8.2 BY END USE, 2025-2035 (USD Million)
    36. | | 7.8.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    37. | | 7.8.4 BY TEST TYPE, 2025-2035 (USD Million)
    38. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    39. | | 7.9.1 BY APPLICATION, 2025-2035 (USD Million)
    40. | | 7.9.2 BY END USE, 2025-2035 (USD Million)
    41. | | 7.9.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    42. | | 7.9.4 BY TEST TYPE, 2025-2035 (USD Million)
    43. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.10.1 BY APPLICATION, 2025-2035 (USD Million)
    45. | | 7.10.2 BY END USE, 2025-2035 (USD Million)
    46. | | 7.10.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    47. | | 7.10.4 BY TEST TYPE, 2025-2035 (USD Million)
    48. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    49. | | 7.11.1 BY APPLICATION, 2025-2035 (USD Million)
    50. | | 7.11.2 BY END USE, 2025-2035 (USD Million)
    51. | | 7.11.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    52. | | 7.11.4 BY TEST TYPE, 2025-2035 (USD Million)
    53. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    54. | | 7.12.1 BY APPLICATION, 2025-2035 (USD Million)
    55. | | 7.12.2 BY END USE, 2025-2035 (USD Million)
    56. | | 7.12.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    57. | | 7.12.4 BY TEST TYPE, 2025-2035 (USD Million)
    58. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    59. | | 7.13.1 BY APPLICATION, 2025-2035 (USD Million)
    60. | | 7.13.2 BY END USE, 2025-2035 (USD Million)
    61. | | 7.13.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    62. | | 7.13.4 BY TEST TYPE, 2025-2035 (USD Million)
    63. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.14.1 BY APPLICATION, 2025-2035 (USD Million)
    65. | | 7.14.2 BY END USE, 2025-2035 (USD Million)
    66. | | 7.14.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    67. | | 7.14.4 BY TEST TYPE, 2025-2035 (USD Million)
    68. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    69. | | 7.15.1 BY APPLICATION, 2025-2035 (USD Million)
    70. | | 7.15.2 BY END USE, 2025-2035 (USD Million)
    71. | | 7.15.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    72. | | 7.15.4 BY TEST TYPE, 2025-2035 (USD Million)
    73. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    74. | | 7.16.1 BY APPLICATION, 2025-2035 (USD Million)
    75. | | 7.16.2 BY END USE, 2025-2035 (USD Million)
    76. | | 7.16.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    77. | | 7.16.4 BY TEST TYPE, 2025-2035 (USD Million)
    78. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    79. | | 7.17.1 BY APPLICATION, 2025-2035 (USD Million)
    80. | | 7.17.2 BY END USE, 2025-2035 (USD Million)
    81. | | 7.17.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    82. | | 7.17.4 BY TEST TYPE, 2025-2035 (USD Million)
    83. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.18.1 BY APPLICATION, 2025-2035 (USD Million)
    85. | | 7.18.2 BY END USE, 2025-2035 (USD Million)
    86. | | 7.18.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    87. | | 7.18.4 BY TEST TYPE, 2025-2035 (USD Million)
    88. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    89. | | 7.19.1 BY APPLICATION, 2025-2035 (USD Million)
    90. | | 7.19.2 BY END USE, 2025-2035 (USD Million)
    91. | | 7.19.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    92. | | 7.19.4 BY TEST TYPE, 2025-2035 (USD Million)
    93. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.20.1 BY APPLICATION, 2025-2035 (USD Million)
    95. | | 7.20.2 BY END USE, 2025-2035 (USD Million)
    96. | | 7.20.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    97. | | 7.20.4 BY TEST TYPE, 2025-2035 (USD Million)
    98. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    99. | | 7.21.1 BY APPLICATION, 2025-2035 (USD Million)
    100. | | 7.21.2 BY END USE, 2025-2035 (USD Million)
    101. | | 7.21.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    102. | | 7.21.4 BY TEST TYPE, 2025-2035 (USD Million)
    103. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.22.1 BY APPLICATION, 2025-2035 (USD Million)
    105. | | 7.22.2 BY END USE, 2025-2035 (USD Million)
    106. | | 7.22.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    107. | | 7.22.4 BY TEST TYPE, 2025-2035 (USD Million)
    108. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    109. | | 7.23.1 BY APPLICATION, 2025-2035 (USD Million)
    110. | | 7.23.2 BY END USE, 2025-2035 (USD Million)
    111. | | 7.23.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    112. | | 7.23.4 BY TEST TYPE, 2025-2035 (USD Million)
    113. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    114. | | 7.24.1 BY APPLICATION, 2025-2035 (USD Million)
    115. | | 7.24.2 BY END USE, 2025-2035 (USD Million)
    116. | | 7.24.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    117. | | 7.24.4 BY TEST TYPE, 2025-2035 (USD Million)
    118. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    119. | | 7.25.1 BY APPLICATION, 2025-2035 (USD Million)
    120. | | 7.25.2 BY END USE, 2025-2035 (USD Million)
    121. | | 7.25.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    122. | | 7.25.4 BY TEST TYPE, 2025-2035 (USD Million)
    123. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.26.1 BY APPLICATION, 2025-2035 (USD Million)
    125. | | 7.26.2 BY END USE, 2025-2035 (USD Million)
    126. | | 7.26.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    127. | | 7.26.4 BY TEST TYPE, 2025-2035 (USD Million)
    128. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    129. | | 7.27.1 BY APPLICATION, 2025-2035 (USD Million)
    130. | | 7.27.2 BY END USE, 2025-2035 (USD Million)
    131. | | 7.27.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    132. | | 7.27.4 BY TEST TYPE, 2025-2035 (USD Million)
    133. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    134. | | 7.28.1 BY APPLICATION, 2025-2035 (USD Million)
    135. | | 7.28.2 BY END USE, 2025-2035 (USD Million)
    136. | | 7.28.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    137. | | 7.28.4 BY TEST TYPE, 2025-2035 (USD Million)
    138. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    139. | | 7.29.1 BY APPLICATION, 2025-2035 (USD Million)
    140. | | 7.29.2 BY END USE, 2025-2035 (USD Million)
    141. | | 7.29.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    142. | | 7.29.4 BY TEST TYPE, 2025-2035 (USD Million)
    143. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    144. | | 7.30.1 BY APPLICATION, 2025-2035 (USD Million)
    145. | | 7.30.2 BY END USE, 2025-2035 (USD Million)
    146. | | 7.30.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    147. | | 7.30.4 BY TEST TYPE, 2025-2035 (USD Million)
    148. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    149. | | 7.31.1
    150. | 7.32 ACQUISITION/PARTNERSHIP
    151. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Application (USD Million, 2025-2035)

  • Diagnosis
  • Vaccination
  • Research
  • Surveillance

Healthcare By End Use (USD Million, 2025-2035)

  • Healthcare
  • Veterinary
  • Pharmaceuticals
  • Research Institutions

Healthcare By Pathogen Type (USD Million, 2025-2035)

  • Brucella abortus
  • Brucella melitensis
  • Brucella suis
  • Brucella canis

Healthcare By Test Type (USD Million, 2025-2035)

  • Serological Tests
  • Molecular Tests
  • Culture Tests
  • Skin Tests
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓